in latest string strategic alliances young biotechnology firms established drug manufacturers gensia pharmaceuticals san diego agreed sell 159 stock $ 15 million marion merrell dow inc the deal gives marion merrell dow right exclusively license manufacture market certain oral drugs gensia developing use new class compounds called purinepyrimidines treat cardiovascular cerebrovascular diseases the drugs may benefit heart attack heart disease victims based kansas city marion merrell dow formed last year dow chemicals merrell dow pharmaceuticals subsidiary merged marion laboratories form $ 2billionplus drug manufacturing marketing company one companys drugs calcium channel blocker called cardizem leading treatment angina hypertension closely held gensia founded 1986 two university california san diego scientists since raised $ 262 million venture capital research development compounds associated purinepyrimidine metabolism president david hale said wednesday the compounds seem effective minimizing tissue damage called ischemia results lack oxygen caused heart attacks if successful drugs could administered acute heart attack victims well chronic sufferers heart disease hale said gensias first product purine compound called ara100 advanced stages clinical trials united kingdom may reach market 1994 hale said the potential market drug least $ 100 million acute applications $ 200 million chronic patients hale said richard stover principal alex brown sons investment bankers new york said marion merrell dowgensia agreement characteristic marions strategy find interesting technology sources products therapeutic areas particularly cardiovascular ischemic heart disease hale president hybritech san diegobased monoclonal antibody company acquired eli lilly $ 485 million 1986 said statement physician officebased market oral drugs gensia developing best served major pharmaceutical company mmd marketing capability financial resources address large markets